Form 4: Twist Bioscience Director Exercises Options, Sells Shares

Twist Bioscience Corp. director Robert Chess exercised stock options and subsequently sold an equal number of shares under a pre-arranged 10b5-1 trading plan.

Summary

• Director Robert Chess acquired 10,000 shares of Twist Bioscience Common Stock by exercising stock options at $11.89 per share.
• Concurrently, Mr. Chess sold 10,000 shares of Common Stock at $47.00 per share.
• These transactions were executed on March 17, 2026, as part of a Rule 10b5-1 trading plan established on December 10, 2025.
• Following these transactions, Mr. Chess directly holds 21,084 shares and indirectly holds 42,528 shares through the Chess 1997 Trust.
• The exercised options had an exercise price of $11.89 and were part of a grant that began vesting on September 13, 2018.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction under a pre-established plan, which is generally neutral. The significant profit realized by the director could be seen as a positive for executive compensation structure.

Positives

• Director Robert Chess realized a significant profit by selling shares at $47.00 after exercising options at $11.89, indicating a substantial gain on vested equity.
• The transactions were conducted under a Rule 10b5-1 trading plan, which suggests pre-planned, orderly sales and reduces concerns about opportunistic insider trading.

Negatives

• A director selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces their direct ownership stake.

Future Outlook

No future outlook or guidance is provided in this Form 4 filing, as it primarily reports insider transactions.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under 10b5-1 plans, are common in the biotechnology sector as executives manage their equity compensation and personal finances. While a sale reduces direct ownership, the pre-planned nature often mitigates concerns about market timing.

Comparison to Industry Standards

• Insider sales under 10b5-1 plans are a standard practice across industries, including biotech, for managing executive compensation and avoiding accusations of trading on material non-public information. There are no specific comparable companies or projects mentioned in this filing to benchmark against, but the execution of a pre-arranged plan is a common and accepted method for insiders to liquidate vested equity.

Related Party Transactions

• The Reporting Person and his spouse are the sole trustees and the sole beneficiaries of the Chess 1997 Trust, which indirectly holds 42,528 shares of Common Stock.

Stakeholder Impact

• Shareholders: The sale by a director could be interpreted in various ways, but the 10b5-1 plan mitigates negative interpretations. The director still retains significant direct and indirect holdings, indicating continued alignment with shareholder interests.

Key Dates

Recommendation

The filing details a routine insider transaction (exercise of options and sale of shares) executed under a pre-established 10b5-1 trading plan. This type of transaction is common for executives managing their equity compensation and does not typically signal a change in the company's fundamental outlook. Therefore, it provides no new information to warrant a change in investment thesis, suggesting a 'hold' recommendation.

Keywords

Twist Bioscience, TWST, Robert Chess, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Director Transaction, Biotechnology